Aurinia Pharmaceuticals Inc. (AUPH) Shares Up 5.6%
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s share price shot up 5.6% during mid-day trading on Friday . The company traded as high as $3.25 and last traded at $3.22, with a volume of 240,560 shares. The stock had previously closed at $3.05.
A number of research firms have recently issued reports on AUPH. Leerink Swann restated an “outperform” rating and issued a $7.00 price target on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 6th. HC Wainwright began coverage on Aurinia Pharmaceuticals in a research note on Thursday, June 30th. They issued a “buy” rating and a $7.00 price target on the stock. Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 5th. Finally, Canaccord Genuity restated a “buy” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, May 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $7.15.
The company has a 50-day moving average price of $2.88 and a 200 day moving average price of $2.65. The company’s market cap is $109.80 million.
Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.